Ichinose H, Ohye T, Suzuki T, Inagaki H, Nagatsu T
Institute for Comprehensive Medical Science, Fujita Health University, Aichi, Japan.
Nihon Shinkei Seishin Yakurigaku Zasshi. 1999 Apr;19(2):85-9.
Tetrahydrobiopterin (BH4) is an essential cofactor for tyrosine hydroxylase. BH4 can be synthesized from GTP through three enzymatic reactions. The rate-limiting step of the BH4 synthesis is catalyzed by GTP cyclohydrolase I (GCH). Recently, we found that GCH is a causative gene for hereditary progressive dystonia/dopa-responsive dystonia (HPD/DRD). However, several problems still remain to be solved. The first concern is the presence of asymptomatic carriers in the disease. The difference between symptomatic and asymptomatic carriers is unknown. Second, we cannot find any mutation in the coding region of the GCH gene in about 40% of the patients. What kind of mutation would be present in these patients. The last concern is the molecular mechanism how the enzymatic activity is decreased to less than 20% of normal values. Further studies are required to solve the questions.
四氢生物蝶呤(BH4)是酪氨酸羟化酶的一种必需辅因子。BH4可通过三步酶促反应由鸟苷三磷酸(GTP)合成。BH4合成的限速步骤由GTP环化水解酶I(GCH)催化。最近,我们发现GCH是遗传性进行性肌张力障碍/多巴反应性肌张力障碍(HPD/DRD)的致病基因。然而,仍有几个问题有待解决。第一个问题是该病存在无症状携带者。有症状和无症状携带者之间的差异尚不清楚。其次,在约40%的患者中,我们在GCH基因的编码区未发现任何突变。这些患者会存在何种突变。最后一个问题是酶活性降低至正常水平的20%以下的分子机制。需要进一步研究来解决这些问题。